<?xml version="1.0" encoding="UTF-8"?>
<p>RDV (GS-5734) as a nucleotide analogue was originally developed to treat Ebola (Tchesnokov et al., 
 <xref rid="CIT0067" ref-type="bibr">2019</xref>). The laboratory assessments has shown that RDV is effective against SARS-CoV (Ju et al., 
 <xref rid="CIT0036" ref-type="bibr">2020</xref>) and MERS-CoV (Gordon et al., 
 <xref rid="CIT0025" ref-type="bibr">2020</xref>) viruses, therefore it can be used as a potential anti-viral agent against SARS-CoV-2 (Khan et al., 
 <xref rid="CIT0037" ref-type="bibr">2020</xref>; Wang et al., 
 <xref rid="CIT0069" ref-type="bibr">2020</xref>). The mechanism of RDV’s anti-viral function is based on the blockage of viral RNA transcription as revealed in molecular examinations using different recombinant viral polymerases (Jordan et al., 
 <xref rid="CIT0034" ref-type="bibr">2018</xref>; Sarma et al., 
 <xref rid="CIT0060" ref-type="bibr">2020</xref>; Tchesnokov et al., 
 <xref rid="CIT0067" ref-type="bibr">2019</xref>; Warren et al., 
 <xref rid="CIT0071" ref-type="bibr">2016</xref>).
</p>
